Huntington Disease Clinical Trial
Official title:
Investigating the Role of the Gut Microbiome in Huntington's Disease
NCT number | NCT06448546 |
Other study ID # | STUDY00006833 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 2024 |
Est. completion date | June 2029 |
The purpose of this study is to find out if there is a connection between the naturally occurring bacteria in our bodies and the progression of Huntington disease. The investigators are trying to determine if patients who are diagnosed with adult-onset HD and who exhibit a rapid rate of disease progression have unique populations of bacteria in their gut as compared to patients with slower progression.
Status | Not yet recruiting |
Enrollment | 36 |
Est. completion date | June 2029 |
Est. primary completion date | June 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | - Inclusion Criteria: - 18 years or older - Provide informed consent - Able to read and speak English - Agree to comply with study procedures - Inclusion criteria for the control group include: - CAG repeat length = 26. - BMI 18.5-24.9 - Inclusion criteria for experimental group 1 include: - BMI < 18.5 (underweight) or significant, involuntary weight loss within the past 12 months. - CAG repeat length 40 - 59. - Documentation of the Clinical Diagnosis of HD with a high level of certainty (>99% confidence) using the validated Unified Huntington's Disease Rating Scale (UHDRS). - Stage I-III on the Functional Assessment component of the UHDRS - Inclusion criteria for experimental group 2 include: - BMI > 25.0 (overweight - obesity) or BMI = 25.0 with significant, unexplained weight gain within the past 12 months - CAG repeat length 40 - 59. - Documentation of the Clinical Diagnosis of HD with a high level of certainty (>99% confidence) using the validated UHDRS. - Stage I-III on the Functional Assessment component of the UHDRS - Exclusion Criteria: - CAG repeat length = 60 to exclude participants with juvenile onset HD. - CAG repeat length 36 - 39 to exclude participants with reduced penetrance. As this is a pilot study, we are primarily interested in participants with typical HD characteristics. - UHDRS Functional Capacity stage = 4 to exclude late-stage HD patients who may be institutionalized and receive nutrition through a feeding tube. - Use of any of the following drugs within the last 6 months: - System antibiotics, antifungals, antivirals, or anti-parasitics (intravenous, intramuscular, or oral) - Corticosteroids (intravenous, intramuscular, oral, nasal, or inhaled) - Cytokines - Methotrexate, immunosuppressive cytotoxic agents, or chemotherapy - Commercial probiotics = 100 million CFU (fermented foods, yogurts, and other homeopathic probiotics and prebiotics do not apply) - Use of topical antibiotics or topical steroids within the last 7 days - History of active, uncontrolled gastrointestinal disorders or diseases, including: - Inflammatory bowel disease - Ulcerative colitis - Crohn's disease - Irritable bowel syndrome - Infectious gastroenteritis, colitis, or gastritis - Clostridium difficile or Helicobacter pylori infection - Persistent or chronic constipation or diarrhea - Acute illness with or without fever at time of sample collection - Positive for HIV, hepatitis B, or hepatitis C - Confirmed or suspected immunodeficient condition/state - Major surgery of the GI tract, excluding cholecystectomy and appendectomy - Unstable dietary history within the past month, such as elimination or significant increase of a major food group in the diet - Recent history of chronic, excessive alcohol consumption - Travel outside of the United States within the last 3 months |
Country | Name | City | State |
---|---|---|---|
United States | University of Central Florida | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Central Florida | University of South Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To quantify relative abundance of entire gut microbiomes in people using Metagenomic analysis | Metagenomic analysis via 16S ribosomal RNA (rRNA) gene sequencing will be performed on HD and control stool samples to identify HD-associated changes in microbe abundance at the genus level. | 5 years | |
Secondary | To quantify relative abundance of candidate microbes in HD and control gut using quantitative PCR. | Using primers specific for microbes responsible for microbiota-derived metabolites that are altered in HD plasma as well as candidate microbes identified through aim 1, quantitative PCR (qPCR) will be used for quantifying relative abundance within the gut at the species level. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Not yet recruiting |
NCT04429230 -
Non-invasive Brain Stimulation in Huntington's Disease
|
N/A | |
Recruiting |
NCT05032196 -
Study of WVE-003 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03599076 -
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
|
||
Terminated |
NCT04617860 -
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05748288 -
Development of the Virtual Unified Huntington's Disease Rating Scale
|
||
Not yet recruiting |
NCT05360082 -
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
|
||
Not yet recruiting |
NCT04370470 -
Development of Assessments for Later Stage HD
|
||
Recruiting |
NCT01834053 -
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
|
Phase 1/Phase 2 | |
Completed |
NCT01458470 -
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
|
Phase 2 | |
Completed |
NCT01357681 -
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
|
Phase 2 | |
Completed |
NCT00980694 -
Bioavailability of Ubiquinol in Huntington Disease
|
Phase 1 | |
Completed |
NCT00146211 -
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|
Phase 3 | |
Recruiting |
NCT01412125 -
Study of Biomarkers That Predict the Evolution of Huntington's Disease
|
N/A | |
Completed |
NCT00075140 -
Family Health After Predictive Huntington Disease (HD) Testing
|
Phase 3 | |
Recruiting |
NCT04818060 -
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
|
||
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Not yet recruiting |
NCT04301726 -
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD
|
Phase 1 | |
Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
Recruiting |
NCT03296176 -
Metabolomic Study in Huntington's Disease (METABO-HD)
|
N/A |